SVB Wealth LLC Makes New Investment in Solventum Co. (NYSE:SOLV)

SVB Wealth LLC bought a new stake in Solventum Co. (NYSE:SOLV) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,468 shares of the company’s stock, valued at approximately $229,000.

Other institutional investors also recently modified their holdings of the company. Modus Advisors LLC bought a new position in shares of Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new position in shares of Solventum in the fourth quarter valued at approximately $26,000. True Wealth Design LLC raised its stake in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after acquiring an additional 471 shares during the last quarter. Crews Bank & Trust bought a new position in shares of Solventum in the fourth quarter valued at approximately $32,000. Finally, Prospera Private Wealth LLC bought a new position in shares of Solventum in the third quarter valued at approximately $35,000.

Solventum Price Performance

SOLV opened at $77.79 on Thursday. The company has a fifty day moving average price of $73.25 and a two-hundred day moving average price of $70.39. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The firm has a market capitalization of $13.44 billion and a PE ratio of 28.29.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Piper Sandler raised their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Wells Fargo & Company raised their price target on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. The Goldman Sachs Group raised their price target on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday. Finally, Morgan Stanley raised their price target on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.